Omni-PAGE?預制膠(Hepes-Tris)
Omni-PAGE?Hepes-Tris Gels
本產品常溫運輸;4℃可保存18個月。切勿置于0℃以下,以免凝膠發生凍裂。
產品組分
產品特點
go
o穩定性高——采用自動化灌膠生產(chan)(chan)技術,確保了(le)產(chan)(chan)品(pin)質量的(de)高(gao)穩(wen)定(ding)性和重復性;
go
o晰——采用玻(bo)璃膠板,有效減少蛋白非特異性吸附,使蛋白條帶更為尖(jian)銳,清晰;
go
o電泳快速——電泳時間短(duan),在150V電壓下,電泳40~50min即可完成;
go
o操作簡便——膠夾(jia)打開(kai)極(ji)為輕松,只(zhi)需用刀(dao)片在膠夾(jia)一(yi)側輕輕劃一(yi)下即可打開(kai);
go
o通用性強——凝膠(jiao)中不含SDS,可用于變(bian)(bian)性(xing)和非(fei)變(bian)(bian)性(xing)電泳(需使用非(fei)變(bian)(bian)性(xing)電泳液);
go
o兼容性強——兼(jian)容市場上主(zhu)流的mini電泳槽,如(ru)Bio-Rad,Invitrogen,天能和君意東方等;
go
o種類多樣——提供多(duo)種濃(nong)(nong)度(du)的(de)均一(yi)膠和梯(ti)度(du)膠。均一(yi)膠可選(xuan)濃(nong)(nong)度(du):8%,10%,12%,15%。梯度膠可選濃度:4~15%,4~20%,8~20%。
產(chan)品簡介
goodOmni-PAGE?預制膠(Hepes-Tris)是(shi)一款安全、快(kuai)捷、高性能的預制(zhi)聚丙烯酰胺(an)凝膠,常(chang)用于PAGE和Western Blot檢測。本預(yu)制膠含有1.5cm高度的4%濃縮膠。丙(bing)烯(xi)酰胺與甲(jia)叉雙丙(bing)烯(xi)酰胺的比例為29:1,凝膠厚度為1.5mm,加樣孔(kong)數(shu)為10孔/15孔,最大上樣(yang)量為60μL/30μL,膠板尺寸:寬×高×厚度為98×84×4.1mm;凝(ning)膠尺(chi)寸為(wei):寬×高×厚(hou)度為(wei)81 × 74×1.5mm。
1. Mei, J., Zhou, W. J., Zhu, X. Y., Lu, H., Wu, K., Yang, H. L., ... & Wang, J. (2018). Suppression of autophagy and HCK signaling promotes PTGS2high FCGR3? NK cell differentiation triggered by ectopic endometrial stromal cells. Autophagy, 14(8), 1376-1397. (IF 16.016)
good2. Ji, L., Qian, W., Gui, L., Ji, Z., Yin, P., Lin, G. N., ... & Gao, W. Q. (2020). Blockade of β-Catenin–Induced CCL28 Suppresses Gastric Cancer Progression via Inhibition of Treg Cell Infiltration. Cancer Research, 80(10), 2004-2016. (IF 12.701)
good3. LI, Jing, et al. Selenium Status in Diet Affects Acetaminophen-Induced Hepatotoxicity via Interruption of Redox Environment. Antioxidants & Redox Signaling, 2021, 34.17: 1355-1367.(IF 8.401)
good4. Li, J., Cheng, P., Li, S., Zhao, P., Han, B., Ren, X., ... & Lu, J. (2020). Selenium status in diet affects acetaminophen-induced hepatotoxicity via interruption of redox environment. Antioxidants and Redox Signaling, (ja). (IF 8.401)
good5. LIU, Suxian, et al. Uncovering the Mechanism of Curcuma in the Treatment of Ulcerative Colitis Based on Network Pharmacology, Molecular Docking Technology, and Experiment Verification. Evidence-Based Complementary and Alternative Medicine, 2021, 2021.(IF 2.629)